EvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs) - Seite 2

Center (EV-TT) is aspiring to become one of the leading European hubs in the EV
field.

Wilfried Haslauer, federal minister of the County of Salzburg, explains the
impact of this new collaboration in the context of the regional science and
innovation strategy framework (WISS 2025): "Life Sciences was identified as one
of Salzburg's strengths which should be further developed and promoted. The
field of exosome research opens up the possibility for Salzburg to achieve
excellence in this field. We are proud that our investments and efforts in this
area, including the opening of the EV-TT center, have been worthwhile. This
cooperation of the Paris Lodron University of Salzburg with two important
economic partners strengthens Salzburg as a location and increases our
international visibility."

Hendrik Lehnert, Rector of the University of Salzburg, adds: " The Paris Lodron
University Salzburg (PLUS) currently undergoes an exciting restructuring process
that will position this University at the edge of life science research and
education. New study programs in Medical Biology and joint projects with the
Paracelsus Medical University will place Salzburg on the map of top biomedical
research. I am convinced that research on extracellular vesicles bears enormous
scientific potential and will not only lead to novel treatment options through
exosomal transport, but will foster the bridging of numerous important research
areas in biology and medicine. This cooperation with EvoBiotiX and Boehringer
Ingelheim will serve as a role model for joint projects between basic research
and industry, from the lab to pharmaceutical manufacturing and clinical
applications. The PLUS is proud to host this large-scale project and will
provide every support to render it a highly successful and long-lasting research
program."

Commenting the announcement, Maarten de Groot, Chief Executive Officer of
EvobiotiX SA notes: " We are extremely excited to create a partnership with
world-class partners in such a dynamic field. By contributing our core
competence of linking the food- and pharmaceutical industry and by creating and
engineering extracts from natural sources, we hope to overcome some of the
critical limitations of traditional EV based approaches ".

Commenting the announcement, Detlev Mennerich, Global Head of RBB states: " It
is at the heart of RBB to explore new therapeutic modalities beyond common paths
which could provide breakthrough innovations for patients. With EvobiotiX and
their core partner Paris Lodron University of Salzburg we are confident to
leverage their unique know-how in the EV field to generate pre-clinical proof of
concept and to pave the ground for highly needed novel therapies. "

About EvoBiotiX

EvoBiotiX SA, is a Ticino based Swiss biotech company. EvoBiotiX focuses on
cross-industry collaborations with food and pharmaceutical companies to create
naturally derived, biologically active macromolecular preparations for
nutraceutical-, veterinary and human pharmaceutical applications.

EvoBiotiX media contact:

mailto:[e-mail]

Additional content: http://presseportal.de/pm/149781/4750714
OTS: EvoBiotiX